following a full submission
apremilast (Otezla®) is accepted for restricted use within NHS Scotland.
Indication under review: alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
SMC restriction: for use in adult patients with active PsA who have had an inadequate response with at least two prior DMARD therapies or who are intolerant to such therapies.
In three phase III, randomised, placebo-controlled studies in patients with active psoriatic arthritis, a significantly greater proportion of patients who received apremilast achieved at least 20% improvement in the American College of Rheumatology response criteria (ACR 20) at 16 weeks compared with those who received placebo.
Download detailed advice193KB (PDF)
Medicine details
- Medicine name:
- apremilast (Otezla) psoriatic arthritis
- SMC ID:
- 1053/15
- Indication:
- alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 June 2015